A hexapeptide VTKFYF from C-terminal part of interleukin-1 receptor antagonist, an inhibitor of IL-1 - IL-1 receptor interaction

Polish Journal of Pharmacology

Volumn 49, Issue 2-3, 1997, Pages 107-117

  Wieczorek, Zbigniew ^a   Kluczyk, Alicja ^b   Słoń Usakiewicz, Jacek J ^b   Siemion, Ignacy Z ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

Author keywords

Inflammation; Interleukin 1; Interleukin 1 receptor antagonist; Thymopentin like sequence

Indexed keywords

HEXAPEPTIDE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; THYMOPENTIN; TUFTSIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; INFLAMMATION; NONHUMAN;

CELL LINE; COLORIMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; INTERLEUKIN-1; INTERLEUKIN-2; OLIGOPEPTIDES; RECEPTORS, INTERLEUKIN-1; STRUCTURE-ACTIVITY RELATIONSHIP; TUFTSIN;

EID: 0030787609     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Arend W. P., Angelo S. D., Joslin F. G.: Regulation of interleukin 1 production in human monocytes. I. Effects of γ-interferon and cycloheximide. Clin. Exp. Immunol., 1988, 74, 377-381.
2. Bolewska-Pedyczak E., Siemion I. Z., Wieczorek Z.: The immunomodulatory activity of peptides related to the DNA contacting loop of p53 protein. J. Peptide Sci., 1996, 2, 318-324.
3. Cebrat M., Wieczorek Z., Siemion I. Z.: Immunosuppressive activity of hymenistatin I. Peptides, 1996, 17, 191-196.
4. Chang J., Ngai P. K., Priestle J. P., Joss U., Vosbeck K. D., Van Ostrum J.: Identification of a reactive lysyl residue (Lys103) of recombinant human interleukin 1β. Mechanism of its reactivity and implication of its functional role in receptor binding. Biochemistry, 1992, 31, 2874-2878.
5. Cominelli F., Bortolami M., Pizarro T. J., Monsacchi L., Ferretti M., Brewer M. T., Eisenberg S. P., Ng R. K.: Rabbit interleukin-1 receptor antagonist. Cloning, expression, functional characterization, and regulation during intestinal inflammation. J. Biol. Chem., 1994, 269, 6962-6971.
6. Dunn C. J.: Cytokines as mediators of chronic inflammatory disease. In: Cytokines and Inflammation. Ed. Kimball E. S., CRC Press, Boca Raton, 1991, 1-34.
7. Eisenberg S. P., Brewer M. T., Verderber E., Heimdal P., Brandhuber B. J., Thompson R. C.: Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family Evolution of a cytokine control mechanism. Proc. Nat. Acad. Sci. USA, 1991, 88, 5232-5236.
8. Evans R. J., Bray J., Childs J. D., Vigers G. P. A., Brandhuber B. J., Skalicky J. J., Thompson R. C., Eisenberg, S. P.: Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1β by site-directed mutagenesis. Identification of a single site in IL-1ra and two sites in IL-1β. J. Biol. Chem., 1995, 270, 11477-11483.
9. Goldstein G., Sheid M. P., Boyse E. A., Schlesinger D. H., Van Wauve J.: A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science, 1979, 204, 1309-1310.
10. Greenfeder S. A., Varnell T., Powers G., Lombard-Gillooly K., Shuster D., McIntyre K. W., Ryan D. E., Levin W., Madison V., Ju, G.: Insertion of a structural domain of interleukin (IL)-1β confers agonist activity to the IL-1 receptor antagonist. Implications for IL-1 bioactivity. J. Biol. Chem., 1995, 270, 22460-22466.
11. Hansen M. M., Nielsen S. E., Berg K.: Reexamination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Method., 1989, 119, 203-210.
12. Haskill S., Martin G., Van Le L., Morris J., Peae A., Bigler C. F., Jaffe G. J., Hammerberg C., Sporn S. A., Fong S., Arend W. P., Ralph P.: cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc. Nat. Acad. Sci. USA, 1991, 88, 3681-3685.
13. Haworth C., Maini R. N., Feldman M.: Prospects for cytokines in human immunotherapy. In: The Cytokine Handbook, 2nd edn. Ed. Thomson A., Academic Press Ltd., London, 1994, 461-487.
14. Hopp T. P., Woods K. R.: A computer program for predicting protein antigenic determinants. Mol. Immunol., 1983, 20, 483-489.
15. Huang J. J., Newton R. C., Horuk R., Matthew J. B., Covington M., Pezzell K., Lin J.: Muteins of human interleukin-1 that show enhanced bioactivity. FEBS Lett., 1987, 223, 294-298.
16. Ju G., Labriola-Tompkins E., Campen C. A., Benjamin W. R., Karas J., Plocinski J., Biondi D., Kaffka K. L., Kilian P. L., Eisenberg S. P., Evans, R. J.: Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis. Proc. Nat. Acad. Sci. USA, 1991, 88, 2658-2662.
17. Karplus P. A., Schulz G. E.: Prediction of chain flexibility in proteins. A tool for the selection of peptide antigens. Naturwissenschaften, 1985, 72, 212-213.
18. Kawakai K., Parker D. C.: Differences between T helper cell typel (Th1) and Th2 cell lines in signalling pathways for induction of contact-dependent T cell help. Eur. J. Immunol., 1992, 22, 85-93.
19. Kawashima H., Yamagishi J., Yamayoshi M., Ohue M., Fukui T., Kotani H., Yamada M.: Structure-activity relationship in human interleukin-1α: identification of key residues for expression of biological activities. Protein Eng., 1992, 5, 171-176.
20. Labriola-Tompkins E., Chandran C., Kaffka K. L., Biondi D., Graves B. J., Hatada M., Madison V. S., Karas J., Kilian P. L., Ju G.: Identification of the discontinous binding site in human interleukin 1β for the type I interleukin 1 receptor. Proc. Nat. Acad. Sci. USA, 1991, 88, 11182-11186.
21. Labriola-Tompkins E., Chandran Ch., Varnell T. V., Madison V. S., Ju G.: Structure-function analysis of human IL-1α: identification of residues required for binding to the human type I IL-1 receptor. Protein Eng., 1993, 6, 535-539.
22. Lennard A. C.: Interleukin-1 receptor antagonist. Crit. Rev. Immun., 1995, 15, 77-105.
23. Lichtman A. H., Chin J., Schmidt J. A., Abbas, A. K.: Role of interleukin-1 in the activation of T lymphocytes. Proc. Nat. Acad. Sci. USA, 1988, 85, 9699-9703.
24. Mosley B., Dower S. K., Gillis S., Cosman D.: Determination of the minimum polypeptide lengths of the functionally active sites of human interleukins 1α and 1β. Proc. Nat. Acad. Sci. USA, 1987, 84, 4572-4576.
25. Mossman T.: Rapid colorimetric assay for cellular growth and cytotoxicity assays. J. Immunol. Method., 1983, 65, 55-63.
26. Mosmann T. R., Coffman R. L.: Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol., 1987, 7, 145-173.
27. Najjar V. A.: Tuftsin, a natural activator of phagocyte cells: an overview. Ann. N. Y. Acad. Sci., 1983, 419, 1-11.
28. Oldfield T. J., Murray-Rust P., Hubbard R. E.: Model structures and action of interleukin 1 and its antagonist. Protein Eng., 1993, 6, 865-871.
29. Parker J. M. R., Guo D., Hodges R. S.: New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry, 1986, 25, 5425-5432.
30. Persico F. J.: Low molecular weight inhibitors of interleukin-1. In: Cytokines and Inflammation. Ed. Kimball E. S., CRC Press, Boca Raton, 1991, 59-88.
31. Schreuder H. A., Rondeau J. M., Tardif C., Soffientini A., Sarubbi E., Akeson A., Bowlin T. L., Yanofski S., Barret R. W.: Refined crystal structure of the interleukin-1 receptor antagonist. Presence of a disulphide link and a cis-proline. Eur. J. Biochem., 1995, 227, 838-847.
32. Schreuder H., Tardif C., Trump-Kallmeyer S., Soffientini A., Sarubbi E., Akeson A., Bowlin T., Yanofski S., Barret R. W.: A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature, 1997, 386, 194-200.
33. Siemion I. Z., Słoń J., Spiegel K., Wieczorek Z.: The evidence on the possible interleukin-1α-tuftsin competition. Arch. Immunol. Ther. Exp., 1991, 39, 605-611.
34. Siemion I. Z., Słoń J., Wieczorek Z.: The immunosuppressive mini-domain of human lactoferrin. J. Peptide Sci., 1995, 1, 295-302.
35. Stockman B. J., Scahill T. A., Strakalaitis N. A., Brunner D. P., Yem A. W., Deibel M. R. Jr.: Solution structure of human interleukin-1 receptor antagonist protein. FEBS Lett., 1994, 349, 79-83.
36. Szewczuk Z., Siemion I. Z., Wieczorek Z.: Immunological properties of the thymopentin-like fragments of HLA-DQ. Mol. Immunol., 1996, 33, 903-905.
37. Vigers G. P. A., Anderson L. J., Gaffes P., Brandhuber B. J.: Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1β. Nature, 1997, 386, 190-194.
38. Vigers G. P. A., Caffes P., Evans R. J., Thompson R. C., Eisenberg S. P., Brandhuber B. J.: X-ray structure of interleukin-1 receptor antagonist at 2.0-A resolution. J. Biol. Chem., 1994, 269, 12874-12879.
39. Welling G. W., Weijer W. J., Van der Zee R., Welling-Wester S.: Prediction of sequential antigenic regions in proteins. FEBS Lett., 1985, 188, 215-218.
40. Wieczorek Z., Słoń J., Kluczyk A., Zbozień R., Stefanowicz P., Siemion I. Z.: The immunomodulatory diversity of the proteins of the transforming growth factor β (TGFβ) family. Int. J. Peptide Prot. Res., 1995, 46, 113-118.
41. Wieczorek Z., Zimecki M., Słoń J. J., Siemion I. Z.: The immunomodulatory activity of tetra- and tripep-tides of tuftsin-kentsin group. Peptides, 1994, 15, 215-221.